At a Glance
- Acquirer: UCB
- Target: Candid Therapeutics
- Deal value: $2 billion upfront, up to $2.2 billion total
- Focus area: T-cell engagers for autoimmune disease
- Next steps: Close in Q2/Q3 2026
What happened?
UCB signed a definitive agreement to acquire Candid Therapeutics, a clinical-stage biotech developing novel T-cell engagers for autoimmune and inflammatory diseases, for $2 billion upfront and up to $200 million in milestones. The transaction is expected to close by the end of the second quarter or in the early third quarter of 2026, pending customary approvals.
Why does it matter?
The deal gives UCB a stronger position in next-generation immunology, where T-cell engagers are emerging as a way to “reset” immune dysfunction rather than just suppress symptoms. Candid’s lead programme, cizutamig, could expand UCB’s reach into severe immune-mediated diseases that still lack durable, targeted treatments.
Who’s behind it?
UCB is a Belgium-based biopharmaceutical company with a growing immunology franchise and an active inorganic growth strategy. Candid is a San Diego- and Shanghai-linked biotech led by Ken Song, who previously sold RayzeBio to Bristol Myers Squibb.
How was it achieved?
Candid has built its T-cell engager pipeline through licensing deals and now has multiple Phase 1 studies underway, with cizutamig targeting BCMA on plasma cells and CD3 on T cells. UCB said the acquisition complements its existing monoclonal antibody work and adds new biologics capabilities for immune reset.
What’s next?
The deal still needs antitrust clearance and other customary closing conditions, but both companies expect completion by mid-2026. If closed, UCB will fold Candid’s TCE programmes into its immunology portfolio and continue advancing them through early clinical development.
What are people saying?
UCB CEO Jean-Christophe Tellier said the acquisition marks a pivotal moment by adding cizutamig and strengthening the company’s innovation strategy. Candid CEO Ken Song said UCB’s immunology expertise should help realise the potential of the pipeline.